Oncotarget

Reviews:

The impact of systemic precision medicine and immunotherapy treatments on brain metastases

Rowland H. Han, Gavin P. Dunn, Milan G. Chheda and Albert H. Kim

PDF  |  Full Text  |  How to cite  |  Order a Reprint

Oncotarget. 2019; 10:6739-6753. https://doi.org/10.18632/oncotarget.27328

Metrics: PDF 483 views  |   Full Text 799 views  |   ?  


Abstract

Rowland H. Han1, Gavin P. Dunn1,2, Milan G. Chheda3,4 and Albert H. Kim1

1 Department of Neurological Surgery, Washington University School of Medicine, St. Louis, MO, USA

2 Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO, USA

3 Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA

4 Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA

Correspondence to:

Albert H. Kim,email: alberthkim@wustl.edu

Keywords: brain metastases; targeted therapy; precision medicine; immunotherapy; systemic therapy

Received: September 22, 2019     Accepted: October 21, 2019     Published: November 19, 2019

ABSTRACT

Metastases from melanoma, lung and breast cancer are among the most common causes of intracranial malignancy. Standard of care for brain metastases include a combination of surgical resection, stereotactic radiosurgery, and whole-brain radiation. However, evidence continues to accumulate regarding the efficacy of molecularly-targeted systemic treatments and immunotherapy. For non-small cell lung cancer (NSCLC), numerous clinical trials have demonstrated intracranial activity for inhibitors of EGFR and ALK. Patients with melanoma brain metastases may benefit from systemic therapy using BRAF-inhibitors with and without trametinib. Several targeted options are available for breast cancer brain metastases that overexpress HER2, although agents with intracranial activity are still needed for other molecular subtypes. Immune checkpoint inhibitors including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies are yielding impressive responses in intracranial manifestations of metastatic melanoma and NSCLC. Given the promising early results with these emerging therapies, management of eligible patients will require increased multidisciplinary discussion incorporating novel systemic treatment approaches prior or in addition to local therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27328